E ndothelial dysfunction is commonly observed in patients with diabetes mellitus (DM) and atherosclerosis 1,2 and is recognized as an independent risk factor for the development of cardiovascular disease. Enhanced inflammation, generation of reactive oxygen species (ROS), and changes in vasoreactivity are characteristics of endothelial dysfunction. 3, 4 Hyperglycemia is a characteristic feature of DM and plays a critical role in DM-associated microvascular complications, 5,6 including endothelial dysfunction. 1,7 Extracellular-signal regulated kinase 5 (ERK5) activation induced by steady laminar flow (s-flow) inhibits leukocyte-endothelial interaction and adhesion molecule expression. [8] [9] [10] [11] [12] Importantly, ERK5 has not only a kinase domain, but also a transcriptional activation domain, the latter of which is regulated by an Background-Diabetes mellitus is a major risk factor for cardiovascular mortality by increasing endothelial cell (EC) dysfunction and subsequently accelerating atherosclerosis. Extracellular-signal regulated kinase 5 (ERK5) is activated by steady laminar flow and regulates EC function by increasing endothelial nitric oxide synthase expression and inhibiting EC inflammation. However, the role and regulatory mechanisms of ERK5 in EC dysfunction and atherosclerosis are poorly understood. Here, we report the critical role of the p90 ribosomal S6 kinase (p90RSK)/ERK5 complex in EC dysfunction in diabetes mellitus and atherosclerosis. Methods and Results-Inducible EC-specific ERK5 knockout (ERK5-EKO) mice showed increased leukocyte rolling and impaired vessel reactivity. To examine the role of endothelial ERK5 in atherosclerosis, we used inducible ERK5-EKO-LDLR −/− mice and observed increased plaque formation. When activated, p90RSK associated with ERK5, and this association inhibited ERK5 transcriptional activity and upregulated vascular cell adhesion molecule 1 expression. In addition, p90RSK directly phosphorylated ERK5 S496 and reduced endothelial nitric oxide synthase expression. p90RSK activity was increased in diabetic mouse vessels, and fluoromethyl ketone-methoxyethylamine, a specific p90RSK inhibitor, ameliorated EC-leukocyte recruitment and diminished vascular reactivity in diabetic mice. Interestingly, in ERK5-EKO mice, increased leukocyte rolling and impaired vessel reactivity were resistant to the beneficial effects of fluoromethyl ketone-methoxyethylamine, suggesting a critical role for endothelial ERK5 in mediating the salutary effects of fluoromethyl ketone-methoxyethylamine on endothelial dysfunction. Fluoromethyl ketone-methoxyethylamine also inhibited atherosclerosis formation in ApoE −/− mice. Conclusions-Our study highlights the importance of the p90RSK/ERK5 module as a critical mediator of EC dysfunction in diabetes mellitus and atherosclerosis formation, thus revealing a potential new target for therapeutic intervention. (Circulation. 2013;127:486-499.)
. p90RSK activation inhibits ERK5 transcriptional activation and regulates subsequent KLF2-eNOS expression and VCAM-1 expression. A, HUVECs were treated with 200 µM H 2 O 2 for indicated times. Cell lysates were immunoprecipitated with anti-ERK5 or immunoglobulin G as a negative control. ERK5-bound p90RSK was detected by Western blotting by using anti-p90RSK antibody (top). p-p90RSK, p90RSK, p-ERK5, ERK5, p-ERK1/2, and tubulin were detected using each specific antibody. Densitometric quantification of ERK5-bound-p90RSK (B), phosphorylation of p90RSK (C), and ERK5 (D). Results were normalized to the lowest association (B) phosphorylation level (C, D) within each set of experiments. Results are expressed relative to untreated cells (0 minutes), and relative to the corresponding band intensity of p90RSK (third from top) (C) or ERK5 (fifth from top) (D) at each time point. Statistical significance was determined by comparison of the average level of the control group with that of each experimental data point. Experiments were conducted in triplicate by using 3 different batches of HUVECs (B through D, mean±SEM, n=3, *P<0.05, **P<0.01 in comparison with control). E, HUVECs were cotransfected with an empty vector or plasmids encoding p90RSK-WT, Gal4-ERK5, and the Gal4-responsive luciferase reporter pG5-Luc. Four hours later, Opti-MEM was replaced by supplemented M200 medium. Eight hours posttransfection, cells were stimulated with 200 µM H 2 O 2 for 16 hours, and ERK5 transcriptional activity was assayed by the dual-luciferase reporter assay. p90RSK overexpression inhibited ERK5 transcriptional activity in a dose-dependent manner, and also enhanced H 2 O 2 -mediated reduction in ERK5 transcriptional activity. Luciferase activity was normalized relative to Renilla luciferase activity. The mean luciferase activity of an empty vector (vehicle treatment) was set as 1 (mean±SEM, n=3). F and G, HUVECs were cotransfected with plasmids encoding Gal4-ERK5 and the Gal4-responsive luciferase reporter pG5-Luc (F) or KLF2 promoter with luciferase (KLF2-Luc) and ERK5 wild-type (G). Cells were also transfected with an empty vector or CA-MEK5α as indicated. Eight hours posttransfection, cells were treated with FMK (10 µM) for 3 hours, followed by stimulation with 200 µM H 2 O 2 for 16 hours. Finally, ERK5 transcriptional activity (F) and KLF2 promoter activity (G) were assayed by a dual-luciferase reporter assay (F and G, mean±SEM, n=3). H and I, MECs were pretreated with FMK-MEA (10 µM, 3 hours), followed by stimulation January 29, 2013 intramolecular interaction independent of ERK5 kinase activity. 11 ERK5/myocyte enhancer factor-2/Kruppel-like factor 2 (KLF2) signaling is involved in the s-flow-mediated endothelial nitric oxide synthase (eNOS) expression and antiinflammatory effects. 13 
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In this study, we focus on the following 2 goals to define novel roles for p90 ribosomal S6 kinase (p90RSK) and ERK5 in endothelial cell (EC) pathophysiology: (1) to determine the role of the p90RSK-ERK5 module in endothelial dysfunction and (2) to investigate the role of p90RSK activation (which causes endothelial dysfunction) on atherosclerosis formation.
Methods
Additional details of the experimental procedures are included in the online-only Data Supplement.
Statistical Analysis
Data are presented as mean±SEM. Statistical analysis was performed with the GraphPad Prism program, version 4.00 (GraphPad Software, Inc, CA). Nonparametric methods were used to analyze differences between independent groups. Differences between 2 groups were analyzed by the Wilcoxon signed rank test; between >2 groups, differences were analyzed by the Kruskal-Wallis test, followed by the Bonferroni multiple-comparison test. (1) The sample size, (2) number of repeated measurements per experiment unit including time intervals, and (3) where the correlation data come from were listed in each figure and figure legend. Probability values <0.05 are accepted as being statistically significant and indicated by one asterisk (*). Two asterisks indicate the probability value is <0.01 (**). Because large numbers of statistical comparisons were performed, all at the 0.05 level of significance may result in the possibility of a type I error.
Results

High Glucose and H 2 O 2 Synergistically Inhibit ERK5-Mediated Functions in a p90RSK-Dependent Manner
Previously, we reported that ROS inhibits ERK5 transcriptional activity. 14, 15 In addition, we also noted that p90RSK is activated by ROS. 16 Therefore, we asked whether p90RSK inhibited ERK5 transcriptional activity in ECs. Because substantial evidence has implicated the role for H 2 O 2 in promoting EC dysfunction and DM-associated cardiovascular complications, 3, 4 we specifically investigated if H 2 O 2 inhibits ERK5 transcriptional activity by activating p90RSK. 14 First, in human umbilical vein endothelial cells, we found that H 2 O 2 -induced p90RSK activation preceded ERK5 activation ( Figure 1A , 1C, and 1D) and that dominant negative ERK5 had no effect on p90RSK kinase activation (online-only Data Supplement Figure IA and IB). These data suggest that p90RSK might negatively regulate ERK5 function in ECs in response to H 2 O 2 , despite the fact that ERK5 has been suggested to be upstream of p90RSK under certain conditions. 17 We found that wild-type (WT)-p90RSK overexpression not only inhibited ERK5 transcriptional activity (measured by cotransfecting ECs with CA-MEK5α, a Gal4-ERK5 fusion construct, and a Gal4-driven luciferase reporter), but also enhanced H 2 O 2 -mediated inhibition of ERK5 transcriptional activity ( Figure 1E ). However, the inhibitory effect of H 2 O 2 on ERK5 transcriptional activity was dose-dependently abolished by a highly selective inhibitor of p90RSK, fluoromethyl ketone-methoxyethylamine (FMK-MEA) 18 ( Figure 1F , online-only Data Supplement Figure IC , and online-only Data Supplement Table I ), suggesting the crucial role for p90RSK activation in ERK5 transcriptional activity. Because ERK5 enhances myocyte enhancer factor-2 activity and subsequently KLF2 promoter activity in ECs, 19 we also tested the effect of p90RSK activation in this context. Similar to the Gal4-ERK5 reporter, H 2 O 2 inhibited ERK5-induced KLF2 promoter activity. Importantly, this inhibitory effect of H 2 O 2 was completely reversed by FMK-MEA ( Figure 1G ), further demonstrating an inhibitory effect of p90RSK kinase activity on ERK5-regulated transcription.
Because H 2 O 2 inhibits s-flow-induced ERK5 transcriptional activity, KLF2 promoter activity, and subsequent eNOS expression, 14 we next asked whether p90RSK mediates these inhibitory effects. ERK5 is activated by s-flow and regulates EC function by increasing eNOS and KLF2 expression and inhibiting EC inflammation. 13 Induction of the KLF2 and eNOS promoter activities by s-flow was counteracted by H 2 O 2 , but DN-p90RSK completely reversed this inhibitory effect (online-only Data Supplement Figure ID) . To model the potential effect of diabetes on p90RSK activation, we also investigated the effect of high glucose (25 mM, HG) on endothelial p90RSK activation. We found that exposure to either HG (25 mM) or low-dose H 2 O 2 (20 µM) by itself could not strongly activate p90RSK (online-only Data Supplement Figure IIA and IIB and data not shown). However, the combination of low-dose H 2 O 2 (20 µM) and HG strongly induced p90RSK activation (online-only Data Supplement Figure IIA and IIB). Mannitol substitution for d-glucose to control for osmotic changes was without effect. In addition, we found that the HG plus low H 2 O 2 condition (HG/low H 2 O 2 ) inhibited ERK5 transcriptional activity in a p90RSK-dependent manner (online-only Data Supplement Figure IIC ). Therefore, we used the HG/low H 2 O 2 condition as an in vitro model for studying a combined effect of HG and ROS (associated . p90RSK interacts with ERK5, phosphorylates ERK5-Ser496, and inhibits ERK5 transcriptional activity. A, HeLa cells were cotransfected with Flag-tagged ERK5 wild type, Xpress-tagged wild-type p90RSK, and a VP16-tagged ERK5 fragment (aa571-807) for 24 hours. Cell lysates were immunoprecipitated with anti-Flag, followed by immunoblotting with anti-p90RSK to determine p90RSK-ERK5 association (top). The expression of p90RSK, ERK5, and the ERK5 fragment were detected by immunoblotting with specific antibodies. The VP16-tagged ERK5 fragment inhibited p90RSK-ERK5 association. Data are representative of 3 independent experiments. B, HUVECs were cotransfected with an empty vector or plasmids encoding an ERK5 fragment (aa571-807) or (aa412-577), Gal4-ERK5, and the Gal4-responsive luciferase reporter pG5-Luc. Cells were also transfected with an empty vector or CA-MEK5α as indicated. Twelve hours posttransfection, cells were stimulated by 200 µM H 2 O 2 for 16 hours, and then ERK5 transcriptional activity was assayed by the dual-luciferase reporter assay as described above. Luciferase activity was normalized relative to Renilla luciferase activity, and the mean luciferase activity at the condition of CA-MEK5α transfection for vehicle treatment was set at the same level. Data are representative of 3 independent experiments (mean ±SEM, n=3). C and D, MECs (passage 3) were transduced with either adenovirus vector containing ERK5 fragment aa571-806 (Ad-ERK5-Fr(571-807)) or Ad-LacZ. After 24 hours of transduction, cells were treated with a combination of high glucose (25 mM) and a low dose of H 2 O 2 (20 µM) for indicated times. C, VCAM-1, PECAM-1, and ERK5 expressions were detected by Western blotting with specific antibodies. D, Densitometric quantification of VCAM-1 expression is shown (mean±SEM, n=3). E, Transcriptional activity of the ERK5 S496A mutant cannot be inhibited by p90RSK. HUVECs were cotransfected for 24 hours with an empty vector or plasmids encoding p90RSK-WT with Gal4-ERK5-WT or a Gal4-ERK5-T475A, -S486A, or -S496A mutant, and a Gal4-responsive luciferase reporter. ERK5 transcriptional activity was assayed by a dual-luciferase reporter assay. Luciferase activity was normalized relative to Renilla luciferase activity, and the mean luciferase activity of an empty vector (p90RSK=0) was set as 1. Data are representative of 3 independent experiments (mean±SEM, n=3). F and G, HUVECs were transduced with either Ad-WT-ERK5 or Ad-ERK5 S496A mutant with Ad-p90RSK or Ad-LacZ as a control for 9 hours. F, ERK5-S496 phosphorylation, ERK5, p90RSK, and tubulin expression were detected by Western blotting with specific antibodies. G, Phosphorylation level of ERK5-S496 was densitometrically quantified with diabetes) on ECs and analyzed the effect in the context of p90RSK activation. We also used advanced glycogen end products and found the involvement of p90RSK activation in advanced glycogen end product-mediated reduction of ERK5 transcriptional activity (online-only Data Supplement Figure IID and IIE), further suggesting the role of endothelial p90RSK-ERK5 module in DM. In mouse endothelial cells isolated from lungs (MECs), HG/low H 2 O 2 inhibited KLF2 mRNA expression, and this effect was reversed by FMK-MEA ( Figure 1H ). Moreover, FMK-MEA inhibited the HG/ low H 2 O 2 -mediated increase in vascular cell adhesion molecule 1 (VCAM-1) mRNA ( Figure 1I ). Finally, overexpression of dominant negative p90RSK was found to counteract the negative and positive effects of HG/low H 2 O 2 on eNOS and VCAM-1 protein levels, respectively ( Figure 1J through 1M). Taken together, these data support a proinflammatory role for p90RSK, which is activated in ECs by stimuli associated with DM (HG and ROS) and which serves to counteract the antiinflammatory program executed by ERK5.
Proinflammatory Effects of p90RSK are Mediated by Complex Formation With ERK5
To begin to explore the mechanism by which p90RSK negatively regulates ERK5 transcriptional activity, we first asked if p90RSK associates with ERK5. In human umbilical vein endothelial cells, endogenous p90RSK coimmunoprecipitated with anti-ERK5 but not with immunoglobulin G control in a manner that was coincident with active but not inactive p90RSK ( Figure 1A and 1B). Two-hybrid experiments indicated that both the NH 2 -terminal kinase (amino acids [aa]1-418) and COOH-terminal transcriptional activation domains (aa571-807) of ERK5 bound to p90RSK, whereas the central segment (aa412-577) did not (online-only Data Supplement Figure  IIIA) . Consistent with the two-hybrid results, the COOH-terminal fragment (aa571-807) blocked the association between p90RSK and full-length ERK5 in a dose-dependent manner ( Figure 2A ). Importantly, this inhibitory ERK5 fragment abolished H 2 O 2 -induced reduction of ERK5 transcriptional activity, whereas the central ERK5 (aa412-577) fragment had no effect ( Figure 2B ). Taken together, these results indicate that inhibition of ERK5 transcriptional activity depends on p90RSK-ERK5 binding, in addition to p90RSK activation.
Next, to examine the role of p90RSK-ERK5 association in increased VCAM-1 expression, we infected MECs with an adenovirus expressing the ERK5 (aa571-807) fragment and found that it significantly blocked VCAM-1 expression induced by HG/H 2 O 2 in MECs ( Figure 2C and 2D). These data provide consistent evidence that p90RSK-ERK5 association is critical for regulation of VCAM-1 expression by p90RSK activation.
p90RSK Inhibits ERK5 Transcriptional Activity by Phosphorylating ERK5-S496
We have reported that p90RSK not only associates with ERK5, but also phosphorylates it at S496. 20 Our analysis using Net-PhosK1.0 further identified ERK5-S433, -T475, -S486, and -S489 as potential phosphorylation sites, and in vitro kinase assays using glutathione S-transferase-tagged ERK5 mutants suggested that T475 and S486 could also be phosphorylated by p90RSK (data not shown). To determine whether these potential phosphorylation sites are involved in ERK5 transcriptional activity, we tested if p90RSK could inhibit transcriptional activity of ERK5 mutants whose potential phosphorylation sites were substituted by Ala. Only ERK5-S496A was resistant to the inhibitory effect of p90RSK ( Figure 2E ), demonstrating that p90RSK regulates ERK5 transcriptional activity via S496 phosphorylation.
To investigate whether ERK5-S496 is actually phosphorylated by p90RSK in cells, we generated antibodies specific to ERK5 phosphorylated at S496 as described in Methods. Western blotting analyses with this antibody show that overexpression of p90RSK stimulated the phosphorylation of WT but not S496A ERK5 ( Figure 2F To investigate the role of p90RSK-mediated ERK5 phosphorylation in the reduction of s-flow-induced eNOS expression by H 2 O 2 , we used an adenovirus-expressing ERK5-S496A (Ad-ERK5-S496A). Of note, we used a relatively high concentration of H 2 O 2 (400 µM) in this set of experiments because of the protective effect of ERK5 overexpression on eNOS reduction, as described previously. 14 
EC-Specific ERK5 Depletion Induces EC Dysfunction and Accelerates Atherosclerosis
Because systemic knockout of ERK5 is lethal in embryos 21 and adults, 15 we generated tamoxifen (4-OHT, 4-hydroxytamoxifen)-inducible EC-specific ERK5 knockout mice (ERK5-EKO) as described in Methods. Sustained (mean±SEM, n=3) . H and I, H 2 O 2 increases ERK5-S496 phosphorylation via p90RSK activation. HUVECs were pretreated with FMK-MEA (10 µM) for 3 hours, then stimulated with H 2 O 2 for indicated times. H, ERK5-S496 phosphorylation, ERK5, p90RSK S380 phosphorylation, p90RSK, and tubulin expression were detected by Western blotting with specific antibodies. I, Densitometric quantification was shown (mean±SEM, n=3). J and K, HUVECs were transduced with either adenovirus vector containing ERK5 wild type (Ad-ERK5-WT) or ERK5-S496A mutant (Ad-ERK5-S496A). After 24 hours of transduction, cells were treated with or without H 2 O 2 (400 µM) and then exposed to s-flow for 24 hours. J, eNOS, ERK5, and tubulin expressions were then detected by Western blotting with their specific antibodies. K, Densitometric quantification was shown (mean±SEM, n=3). aa indicates amino acids; eNOS, endothelial nitric oxide synthase; ERK5, extracellular-signal regulated kinase 5; FMK-MEA, fluoromethyl ketone-methoxyethylamine; HUVECs, human umbilical vein endothelial cells; MEC, mouse endothelial cell; p90RSK, p90 ribosomal S6 kinase; PECAM-1, platelet/endothelial cell adhesion molecule 1; VCAM-1, vascular cell adhesion molecule 1; and WT, wild type. Figure 3A ). In the spleen lysate of inducible ERK5-EKO −/− mice, we found no reduction of ERK5 in comparison with that of the VE-Cad-CreER T2 -WT control after 2 weeks of 4-OHT injection, also indicating that the reduced ERK5 is endothelial specific ( Figure 3B ).
ERK5 has been shown to be a critical regulator of KLF2, which in turn regulates eNOS expression and counteracts EC inflammation 13, 14 in vitro. We, therefore, assayed the expression of anti-and proinflammatory factors in inducible ERK5-EKO +/− mice after 2 weeks of 4-OHT injection. eNOS expression was decreased, whereas the expression of VCAM-1 and E-selectin was increased in MECs isolated from 4-OHT-treated mice in comparison with that of vehicle-treated mice ( Figure 3A) . With regard to apoptosis, no difference was noted in the basal level of cleaved caspase-3 expression or transferase-mediated dUTP nick end-labeling-positive cells in the 2 groups of mice ( Figure  3A and online-only Data Supplement Figure IVA) . To exclude possible deleterious effects of 4-OHT on ECs, we used noninducible EC-specific ERK5 knockout mice (VE-Cad-Cre/ERK5 flox/flox ; noninducible ERK5-EKO −/− ) that were of the same age as the 4-OHT-inducible animals. We found similar effects on eNOS, VCAM-1, and E-selectin expression as in the inducible ERK5-EKO +/− mice (onlineonly Data Supplement Figure IVB ). Up to 6 months of age, we did not observe any differences in size or body weight between homo-or heterozygous ERK5-EKO mice and nontransgenic littermate control mice, and no notable differences were found on their development, life span, and tissue structures at a gross anatomic level. In addition, we found no differences in the expression of ERK5, eNOS, VCAM-1, E-selectin, total and phospho-p90RSK (Ser380) between vehicle-and 4-OHT-treated VE-Cad-CreER T2 /WT mice (online-only Data Supplement Figure IVC) . ). Individual red signals and merged images, as well, are shown as indicated. Two weeks after STZ injection, blood glucose level was measured. Insulin (Ins) (Humalin N, twice daily, 5 IU/kg) treatment was started after 3 days of STZ injection. Scale bars, 50 µm. B, Glucose tests in the blood of male mice after insulin treatment followed by injection of vehicle or STZ. C and D, En face confocal images of diabetic and nondiabetic mice in s-flow area (greater curvature of aortic arch area) were obtained by using the same image acquisition setting, and fluorescence intensity was quantified. Data are shown as means±SEM. E, C57BL/6 wild-type mice were intraperitoneally injected for 3 days with vehicle or STZ (100 mg/kg per day), followed by vehicle or FMK-MEA injection as described in Figure 5A . After 4 days of FMK-MEA injection, MECs were isolated from the lungs of these mice as described in Methods. Immediately, RIPA buffer was added to lyse the cells, then p-p90RSK (upper) and total p90RSK (lower) protein expressions were assayed by Western blotting by using each specific antibody (n=3). FMK-MEA, fluoromethyl ketone-methoxyethylamine; MEC, mouse endothelial cell; p90RSK, p90 ribosomal S6 kinase; RIPA, radioimmunoprecipitation assay; s-flow, steady laminar flow; STZ, streptozotocin; and veh, vehicle. In comparison with nondiabetic mice, vasodilatation in STZ-treated diabetic mice was significantly diminished. FMK treatment improved vessel reactivity to Ach in STZ-treated diabetic mice. Data are shown as means±SEM, **P<0.01 compared with STZ treatment group (n=3). E through H, C57BL/6 wild-type mice were intraperitoneally injected for 3 days with vehicle or STZ (100 mg/kg per day), followed by vehicle or FMK-MEA injection as described in Figure 5A . After 4 days of FMK-MEA injection, MECs were isolated from the lungs of these mice, and then (for E through G) RNA was immediately extracted for real-time PCR. VCAM-1 mRNA (E), E-selectin mRNA (F), eNOS mRNA (G) levels were detected by qRT-PCR as described in Methods. H, RIPA buffer was added to lyse the cells, then E-selectin (upper) and PECAM-1 (lower) protein January 29, 2013
To evaluate a functional role of the reduced endothelial ERK5, we studied leukocyte rolling and acetylcholine-induced vasodilation in the mesentery of inducible ERK5-EKO +/− mice. Leukocyte rolling was increased in the 4-OHT-treated group in comparison with that of the vehicle-treated group (Figure 3D , and online-only Data Supplement Movie I). No changes were observed in venular diameter or shear rate under these conditions ( Figure 3C ). Acetylcholine-induced vasodilation was significantly decreased in both inducible heterozygous ERK5-EKO +/− and homozygous ERK5-EKO −/− mice in comparison with the 4-OHT-treated control VE-Cad-CreER T2 /WT mice ( Figure 3E ). It is remarkable that phenotypes with inducible KO of 1 allele and constitutive KO of both alleles are identical, suggesting that ECs are extremely sensitive to ERK5 dosage. EC-independent vasodilation by sodium nitroprusside was indistinguishable between inducible ERK5-EKO and VE-Cad-CreER T2 /WT mice (online-only Data Supplement Figure IVD) , indicating the critical role of ERK5 in EC-mediated vasodilation.
To examine the role of endothelial ERK5 in atherosclerosis formation, inducible ERK5-EKO-LDLR −/− mice were fed with a high-cholesterol diet for 16 weeks. In comparison with the control mice, no difference either in body weight (onlineonly Data Supplement Figure VB) , glucose tolerance test (online-only Data Supplement Figure VA) , or plasma cholesterol level (online-only Data Supplement Figure VC) in inducible ERK5-EKO −/− ; LDLR −/− mice was noted. However, we observed a significant increase in both surface area and size of lesions in the aortic root of these mice in comparison with the aortic root of the control ( Figure 3F ). These data suggest a critical role of ERK5 in EC dysfunction and subsequent atherosclerosis formation.
p90RSK Expression and Phosphorylation are Increased in DM Mouse Aorta
To confirm that DM increases endothelial p90RSK activation, we analyzed the localization and expression of both total and phospho-p90RSK (p-p90RSK) in en face preparations of mouse endothelium derived from streptozotocin (STZ)induced diabetic mice ( Figure 4A ) by using a laser-scanning confocal microscope. The STZ effect in inducing DM in mice was confirmed by the increase in blood glucose levels. This increase was reduced to the normal level when STZ-injected mice were treated twice daily with insulin (Humalin N, 5 IU/ kg) after 3 days of STZ injection ( Figure 4B ). Figure 4A shows the effect of hyperglycemia on both p-p90RSK and total p90RSK expressions in vehicle-, STZ-, and STZ + insulin-treated mice in the same steady laminar flow area (greater curvature area at aortic arch). The antip-p90RSK staining signal was significantly increased in STZtreated mice. Note that both p-p90RSK ( Figure 4A, upper) and total p90RSK ( Figure 4A , lower) are mainly localized in the nucleus. Based on fluorescence-staining intensities, there was a significant decrease in p-p90RSK in aortae derived from insulin-treated diabetic mice in comparison with that of the untreated mice ( Figure 4A, 4C, and 4D ). Furthermore, we detected the endothelial p90RSK activation in MECs isolated from STZ-treated mice by Western blotting and confirmed a significant increase in p90RSK activation in comparison with vehicle-treated mice ( Figure 4E ). Taken together, these data suggest that the observed increase in p90RSK activation in STZ-treated mice is due to hyperglycemia.
FMK-MEA, a Selective p90RSK Inhibitor, Reverses DM-mediated EC Dysfunction
Leukocyte rolling and adhesion are characteristics of vascular inflammation, and vascular reactivity to ACh is an indicator of vascular function. Increased leukocyte rolling 22 and decreased ACh-induced vasodilation 23 in DM have been reported. In STZ-treated mice, leukocyte rolling was increased and AChinduced vasodilation was dampened in comparison with those of the vehicle-treated mice ( Figure 5A through 5C, and online-only Data Supplement Movie II). To study the involvement of p90RSK activation in the observed vascular inflammation and dysfunction in STZ-treated mice, FMK-MEA was used. FMK-MEA (online-only Data Supplement Figure VIA) is a more soluble and metabolically stable version of FMK, 19 a selective and irreversible inhibitor of p90RSK1, p90RSK2, and p90RSK4. To show the specificity of FMK-MEA, we used the Ambit/DiscoverX platform to screen 443 kinases and measured the apparent binding constant (K d ) to a given inhibitor. We found that all kinases, with the exception of RSK1/4 CTD, bound with K d >>1 µM, which was performed in vitro against recombinant kinase domains (online-only Data Supplement Table I ). Treatment of mice with FMK-MEA at the highest dose of 50 mg/kg inhibited p90RSK1 by >95% and p90RSK2 by ≈80% in mouse heart tissue (online-only Data Supplement Figure VIB) . First, we found that the increase of p90RSK activation in MECs isolated from STZ-treated mice was significantly inhibited by FMK-MEA treatment ( Figure  4E ). Next, we observed a dose-dependent inhibitory effect of FMK-MEA on leukocyte rolling in diabetic mice ( Figure 5A through 5C, and online-only Data Supplement Movie II). The dose dependence of this effect correlated with p90RSK1/2 inhibition (online-only Data Supplement Figure VIB) . Insulin treatment also reduced leukocyte rolling ( Figure 5A through 5C, and online-only Data Supplement Movie II), in agreement with in vitro data suggesting that increased leukocyte rolling and adhesion is caused by HG 24 and not by STZ side effects. Figure 5D ). Of note, vasodilation induced by sodium nitroprusside was the same in STZ-treated and control mice (online-only Data Supplement Figure VIE) .
To determine the role of p90RSK activation in the expression of proinflammatory adhesion molecules and anti-inflammatory eNOS in DM mice, we quantified mRNA levels of VCAM-1, E-selectin, and eNOS in MECs isolated from STZinduced DM or control mice. STZ diabetic mice exhibited a higher VCAM-1 and E-selectin mRNA expression but a lower eNOS mRNA expression in comparison with that of the control mice ( Figure 5E through 5G) . Strikingly, FMK-MEA reversed the effect of STZ-induced DM on the expression of VCAM-1, E-selectin, and eNOS ( Figure 5E through 5G) . We confirmed that FMK-MEA treatment resulted in reduced E-selectin expression at the protein level as well ( Figure 5H) .
To confirm the importance of p90RSK activation in EC function in another DM model, we used C57BL/6J-Ins2 Akita (Akita) mice, known to be hyperglycemic at 7 weeks of age 25 ( Figure 6A ). Similar to STZ-treated mice, enhanced recruitment of leukocytes to EC and EC dysfunction were observed in Akita mice in comparison with age-matched littermate controls ( Figure 6B , and online-only Data Supplement Movie III). FMK-MEA treatment significantly decreased leukocyte rolling and improved ACh-induced vasodilation (Figure 6B and 6C, and online-only Data Supplement Movie III). Using molecular approaches, we generated endothelial-specific VE-Cad-CreER T2 -WT-p90RSK-Tg mice (EC-WT-p90RSK-Tg) to further ascertain these observations. In the inducible EC-WT-p90RSK-Tg mice, we confirmed increased p90RSK expression after 4-OHT treatment in comparison with VE-Cad-CreER T2 -WT control mice ( Figure 6D ). We found that leukocyte rolling in the inducible EC-WT-p90RSK-Tg mice was significantly upregulated than VE-Cad-CreER T2 -WT control mice after 4-OHT injection ( Figure 6E , and online-only Data Supplement Movie IV). Taken together, our findings indicate a critical role for p90RSK activation in EC inflammation and dysfunction in the diabetic state.
EC-Specific ERK5 Depletion Eliminates the Beneficial Effect of FMK-MEA
To test whether ERK5 mediates the beneficial effects of FMK-MEA in DM-induced inflammatory events, we assayed leukocyte rolling and acetylcholine-induced vasodilation in inducible ERK5-EKO −/− mice with STZ-induced DM. Leukocyte rolling was increased and acetylcholine-induced vasodilation was decreased in 4-OHT-treated mice ( Figure 7A through 7C, and online-only Data Supplement Movie III). Interestingly, FMK-MEA had no effect on leukocyte rolling and vessel reactivity in this context ( Figure 7A through 7C, and online-only Data Supplement Movie V), suggesting a critical role for endothelial ERK5 in mediating the salutary effects of FMK-MEA on DM-induced endothelial dysfunction.
FMK-MEA Inhibits Atherosclerosis Formation
As p90RSK activation is critical for DM-mediated EC inflammation and dysfunction, processes well known to initiate atherogenesis, 1, 26 we explored the role for p90RSK activation in atherogenesis. Atherosclerosis was induced in ApoE −/− mice as described in Methods. 27 With a normal chow diet and lowdose angiotensin II , atherosclerosis was accelerated without abdominal aorta aneurysms. Under those conditions, FMK-MEA significantly inhibited the formation of atherosclerotic lesions ( Figure 8A) . No difference in plasma cholesterol levels was observed in experimental groups (online-only Data Supplement Figure VIF) . With a high-fat diet and high-dose angiotensin II, both atherosclerosis and abdominal aorta Figure 8B ). Again, FMK-MEA inhibited atherosclerosis formation in the arch and upper part of the descending aorta ( Figure 8B ). However, no inhibitory effect of FMK-MEA was observed on abdominal aorta aneurysms formation (data not shown).
Discussion
We have identified 2 key molecules that are involved in DMmediated EC dysfunction and a drug that disrupts the regulatory connections between these molecules. Our study strongly suggests that DM activates p90RSK, which directly inhibits the transcriptional activity of ERK5, an atheroprotective nonclassical mitogen-activated protein kinase. This induces inflammatory responses in ECs and promotes vascular dysfunction. First, we found a significant increase in leukocyte rolling and reduction in vessel reactivity in mesenteric vessels of inducible ERK5-EKO mice. Next, increased p90RSK activity in ECs was induced by HG both in vivo and in vitro. FMK-MEA, a specific inhibitor of p90RSK, counteracted DM-mediated EC inflammation and dysfunction, indicating the key role of p90RSK activation in DM. Interestingly, FMK-MEA could not improve these conditions in ERK5-EKO mice, suggesting the critical role of ERK5 in FMK-MEA-mediated improvement of EC function. Last, we found that FMK-MEA significantly inhibited, and the depletion of endothelial ERK5 accelerated, atherosclerosis formation in ApoE −/− and LDL −/− mice, confirming the importance of the p90RSK-ERK5 module in clinically relevant end points of atherosclerosis.
We think that these data provide strong evidence for the key role of the p90RSK-ERK5 module in endothelial dysfunction and atherosclerosis formation. Although the role of this module on endothelial dysfunction in vivo was further demonstrated by eliminating the beneficial effect of FMK-MEA in EC-specific ERK5 depletion mice, the role of endothelial ERK5 in p90RSK-mediated atherosclerosis formation remains unclear. Further investigation will be necessary to prove this.
An expanded Discussion section is available in the onlineonly Data Supplement.
